205 related articles for article (PubMed ID: 23556081)
1. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult hodgkin lymphoma patient.
Straus DJ
Ther Adv Hematol; 2011 Apr; 2(2):111-9. PubMed ID: 23556081
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Cost-Effectiveness of Survivorship Care for Survivors of Hodgkin Lymphoma (INSIGHT Study): Protocol for a Multicenter Retrospective Cohort Study With a Quasi-Experimental Design.
Lammers EMJ; Zijlstra JM; Retèl VP; Aleman BMP; van Leeuwen FE; Nijdam A;
JMIR Res Protoc; 2024 Apr; 13():e55601. PubMed ID: 38635308
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Survivorship Care Practices and Late Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma.
Frick MA; Vachani CC; Hampshire MK; Bach C; Arnold-Korzeniowski K; Metz JM; Hill-Kayser CE
JCO Clin Cancer Inform; 2018 Dec; 2():1-10. PubMed ID: 30652594
[TBL] [Abstract][Full Text] [Related]
4. Late complications after treatment for Hodgkin lymphoma.
Ng AK
Curr Hematol Malig Rep; 2008 Jul; 3(3):119-25. PubMed ID: 20425456
[TBL] [Abstract][Full Text] [Related]
5. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.
van Leeuwen FE; Ng AK
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):323-330. PubMed ID: 27913498
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.
Minn AY; Riedel E; Halpern J; Johnston LJ; Horning SJ; Hoppe RT; Goodman KA
Br J Haematol; 2012 Nov; 159(3):329-39. PubMed ID: 22966754
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported distress in Hodgkin lymphoma across the survivorship continuum.
Troy JD; Locke SC; Samsa GP; Feliciano J; Richhariya A; LeBlanc TW
Support Care Cancer; 2019 Jul; 27(7):2453-2462. PubMed ID: 30377801
[TBL] [Abstract][Full Text] [Related]
8. Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects.
Ng AK
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):488-94. PubMed ID: 25696899
[TBL] [Abstract][Full Text] [Related]
9. Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects.
Ng AK
Blood; 2014 Nov; 124(23):3373-9. PubMed ID: 25428219
[TBL] [Abstract][Full Text] [Related]
10. Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
Mounier N; Anthony S; Busson R; Thieblemont C; Ribrag V; Tilly H; Haioun C; Casasnovas RO; Morschhauser F; Feugier P; Delarue R; Ysebaert L; Sebban C; Broussais-Guillaumot F; Damaj G; Nerich V; Jais JP; Laborde L; Salles G; Henry-Amar M
Cancer; 2019 Jul; 125(13):2291-2299. PubMed ID: 30901086
[TBL] [Abstract][Full Text] [Related]
11. Employment status and health related quality of life among Hodgkin-lymphoma survivors'- results based on data from a major treatment center in Hungary.
Magyari F; Kósa K; Berecz R; Illés A; Miltényi Z; Simon Z; Illés Á
Health Qual Life Outcomes; 2017 Sep; 15(1):180. PubMed ID: 28927453
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance.
Ng AK; van Leeuwen FE
Semin Hematol; 2016 Jul; 53(3):209-15. PubMed ID: 27496313
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
Lavoie JC; Connors JM; Phillips GL; Reece DE; Barnett MJ; Forrest DL; Gascoyne RD; Hogge DE; Nantel SH; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Voss NJ; Nevill TJ
Blood; 2005 Aug; 106(4):1473-8. PubMed ID: 15870180
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of late effects during a 21-year follow-up of pediatric Hodgkin lymphoma survivors: Experience of a pediatric cancer center in Turkey, as a developing country model.
Tacyildiz N; Cakmak HM; Unal E; Dincaslan H; Tanyıldız G; Özdemir SI; Kartal Ö; Yılmaz Y; Yavuz G; Kuzu I
Indian J Cancer; 2024 Jan; ():. PubMed ID: 38195683
[TBL] [Abstract][Full Text] [Related]
15. Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care.
Damlaj M; El Fakih R; Hashmi SK
Blood Rev; 2019 Jan; 33():63-73. PubMed ID: 30093158
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of function-limiting late effects in Hodgkin lymphoma survivors.
Enam N; Chou K; Stubblefield MD
PM R; 2022 Jul; 14(7):811-817. PubMed ID: 34181821
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin lymphoma: the follow-up of long-term survivors.
Hodgson DC
Hematol Oncol Clin North Am; 2008 Apr; 22(2):233-44, vi. PubMed ID: 18395147
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.
Majhail NS; Bajorunaite R; Lazarus HM; Wang Z; Klein JP; Zhang MJ; Rizzo JD
Br J Haematol; 2009 Oct; 147(1):129-39. PubMed ID: 19573079
[TBL] [Abstract][Full Text] [Related]
19. [The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment].
Dekker N; van 't Veer MB; Aleman BM; van Leeuwen FE; Raemaekers JM
Ned Tijdschr Geneeskd; 2015; 159():A9269. PubMed ID: 26577382
[TBL] [Abstract][Full Text] [Related]
20. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood.
Matasar MJ; Ford JS; Riedel ER; Salz T; Oeffinger KC; Straus DJ
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25717170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
